The Top Line
Inside this year’s ASCO: Biggest data drops, trends and the best exhibit booth
Jun 14, 2024
Fierce Biotech and Fierce Pharma reporters Gabrielle Masson and Angus Liu discuss ASCO's biggest data drops and trends. They share insights on Keytruda's competition, Merck's strategic shift, and novel cancer vaccines. Experience the ASCO exhibit hall adventures with virtual reality and unique booth encounters. Learn about the intense competition, challenges, and amusing moments at the international conference.
13:35
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Summit Therapeutics and Akiso's bi-specific antibody drug outperformed Keytruda in lung cancer trial, impacting treatment strategies.
- Merck's collaboration with Moderna on an mRNA cancer vaccine showed promising results and potential regulatory advantages.
Deep dives
Bi-Specific Antibody Drug Triumphs Over Keytruda in Lung Cancer Study
A significant highlight at ASCO this year was the revelation of a bi-specific antibody drug from Summit Therapeutics and Akiso, a Chinese biotech, surpassing Keytruda in a head-to-head clinical trial for PD-L1 positive non-small cell lung cancer. This groundbreaking achievement marked the first time a single drug outperformed Keytruda in such a context, causing both companies' market shares to soar. The discussion surrounding this triumph dominated conversations at the conference, highlighting its potential impact on lung cancer treatment strategies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
